STOCK TITAN

Aurora Cannabis Inc. Common Shares - ACB STOCK NEWS

Welcome to our dedicated page for Aurora Cannabis Common Shares news (Ticker: ACB), a resource for investors and traders seeking the latest updates and insights on Aurora Cannabis Common Shares stock.

Aurora Cannabis Inc. (NASDAQ: ACB, TSX: ACB) is a prominent Canadian company headquartered in Edmonton, Alberta, dedicated to the cultivation, production, and sale of high-quality cannabis for both medical and recreational use. The company's state-of-the-art facilities in Alberta embody advanced cultivation techniques that ensure the highest standards of quality, reliability, and safety in their products. Aurora's comprehensive portfolio includes renowned brands like Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, catering to a wide range of consumer preferences.

Aurora's operations extend beyond Canada, with significant international presence through medical cannabis exporting agreements. A notable subsidiary, Australis Capital Inc., plays a crucial role in participating in the U.S. cannabis market. The company's commitment to quality is further highlighted by its EU-GMP and TGA-GMP certified production facilities, ensuring compliance with rigorous international standards.

In recent developments, Aurora has launched three new cannabis-infused beverages targeted initially at veteran patients. These products, featuring innovative SōRSE® emulsion technology, offer an alternative form of cannabis consumption without the strong cannabis aroma or taste. Available in flavors like Neon Rush, Strawberry Pineapple Tropical Fizz, and Pineapple Coconut Fizz, these beverages are designed to enhance patient wellbeing with a refreshing and potent experience.

Financially, Aurora has achieved significant milestones, including the repayment of nearly $465 million in convertible debt and forecasting positive free cash flow for calendar 2024. The company has also strengthened its global footprint by acquiring MedReleaf Australia's majority equity, further solidifying its position in the Australian market. Aurora’s commitment to financial discipline and strategic expansions underscores its potential for sustainable growth.

Aurora's dedication to innovation and patient care is exemplified through its continuous development of new products and partnerships. Their recent launches include resin cartridges and pastilles in Australia, expanding their product range and enhancing patient access to premium medical cannabis. Additionally, the company's strategic moves in Europe, particularly in Germany, position it as a leader in the evolving cannabis landscape.

With a robust pipeline of products and strategic market expansions, Aurora Cannabis Inc. continues to pave the way for significant advancements in the global cannabis industry, committed to improving lives through high-quality, innovative cannabis products.

Rhea-AI Summary
Aurora Cannabis Inc. applauds Germany's cannabis legalization, expecting it to boost the medical cannabis market expansion in the country. The reclassification of cannabis as a non-narcotic will enhance patient access and education, benefiting Aurora's position as a leading provider of medical cannabis in Germany.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.82%
Tags
none
-
Rhea-AI Summary
Aurora Cannabis Inc. achieves Good Manufacturing Practice certification from Australia's Therapeutic Goods Administration for its Canadian production facilities, enhancing its position in the Australian medical cannabis market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.49%
Tags
none
-
Rhea-AI Summary
Aurora Cannabis Inc. and MedReleaf Australia have launched medical cannabis pastilles in Australia, offering greater choice for patients. The pastilles come in three formats, including THC, CBD, and balanced options. MedReleaf Australia aims to provide consistent and high-quality products to Australian patients, with plans for future innovations under the Aurora and IndiMed brands.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.42%
Tags
none
Rhea-AI Summary
Aurora Cannabis Inc. announces the repayment of $7.2 million in convertible senior notes, marking a significant milestone in reducing debt. The total cash cost, including accrued interest, amounts to $7.4 million. The remaining debt of $47.9 million is related to Bevo Farms Ltd. CEO Miguel Martin highlights the company's focus on balance sheet strength and financial discipline to achieve positive free cash flow this year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.96%
Tags
none
-
Rhea-AI Summary
Aurora Cannabis Inc. partners with Script Assist to empower UK patients with high-quality medical cannabis products and guidance. The partnership aims to enhance the UK medical cannabis landscape by providing access to premium products and valuable information through an innovative technology platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
partnership
-
Rhea-AI Summary
Aurora Cannabis Inc. appoints Simona King, a former Bristol Myers-Squibb executive, as the new Chief Financial Officer. The company also completes a share consolidation on a 10 to 1 basis, with trading under the symbol 'ACB' on NASDAQ and TSX.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.7%
Tags
none
Rhea-AI Summary
Aurora Cannabis Inc. re-affirms its commitment to achieving positive free cash flow in 2024 and delivers its fifth consecutive quarter of positive adjusted EBITDA. The company has become the largest global medical cannabis company in nationally legal markets following the acquisition of MedReleaf Australia, and has experienced strong YoY growth in high-margin international net cannabis revenue. They reported a cash position of over $200 million and expect to fully repay remaining convertible debt of $7.3 million in February. The company's fiscal 2024 is on track to be their strongest year yet, with 41% YoY growth in international medical net revenue. They also anticipate achieving positive adjusted EBITDA on an annualized basis for the first time in fiscal 2024. The acquisition of MedReleaf Australia is expected to be immediately accretive to Adjusted EBITDA, while accelerating their path to generate positive free cash flow this calendar year. Aurora expects steady revenue from Canadian medical and consumer segments, modest growth in Europe and Australia, and seasonally higher revenues and gross profit from plant propagation in fiscal Q4 2024. They have repurchased approximately $23.1 million in principal amount of convertible debentures and expect to be debt-free by the end of February 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.03%
Tags
-
Rhea-AI Summary
Aurora Cannabis Inc. has acquired the remaining 90% equity interest of MedReleaf Australia for AUD$50 million, making it the largest global medical cannabis company operating in nationally legal markets. The transaction is expected to be immediately accretive to Adjusted EBITDA and accelerate the Company's plan for Positive Free Cash Flow generation in 2024. The Australian medical cannabis market is rapidly growing and is estimated to be worth approximately AUD$400 million, with MedReleaf Australia holding the #2 position in the market. The acquisition is a strategic milestone for Aurora, strengthening its presence in Australia and supporting its path to profitability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.03%
Tags
-
Rhea-AI Summary
Aurora Cannabis Inc. re-affirms its expectation of positive annual Adjusted EBITDA for fiscal 2024 and positive Free Cash Flow generation in calendar 2024. The company also announces its intention to consolidate common shares and schedules its Q3 2024 investor conference call for February 8, 2024. Adjusted EBITDA is expected to be positive on an annual basis in fiscal 2024, and management continues to expect positive free cash flow in calendar 2024. The Board of Directors has approved a plan to consolidate all outstanding Common Shares on the basis of 1 Common Share for every 10 Common Shares currently outstanding.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.04%
Tags
Rhea-AI Summary
Aurora Cannabis Inc. (ACB) announces the launch of three new cannabis-infused beverages exclusively for veteran patients, available at Aurora Medical. The products, produced by Vacay and Versus, offer THC, CBD, and CBG options in three fruity flavors. The company aims to meet the needs of patients seeking alternative forms of cannabis to support their wellbeing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.31%
Tags
none

FAQ

What is the current stock price of Aurora Cannabis Common Shares (ACB)?

The current stock price of Aurora Cannabis Common Shares (ACB) is $4.23 as of November 18, 2024.

What is the market cap of Aurora Cannabis Common Shares (ACB)?

The market cap of Aurora Cannabis Common Shares (ACB) is approximately 233.5M.

What is Aurora Cannabis Inc. primarily known for?

Aurora Cannabis Inc. is known for the cultivation, production, and sale of high-quality cannabis products for both medical and recreational use.

Where is Aurora Cannabis Inc. headquartered?

Aurora Cannabis Inc. is headquartered in Edmonton, Alberta, Canada.

What are some of the brands under Aurora Cannabis?

Some of the brands under Aurora Cannabis include Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard.

What recent products has Aurora Cannabis launched?

Aurora Cannabis recently launched three new cannabis-infused beverages and resin cartridges in Australia, catering to patient needs with innovative and high-quality products.

What is Aurora's financial outlook for 2024?

Aurora expects to achieve positive free cash flow in calendar 2024 and has recently completed the repayment of nearly $465 million in convertible debt.

What significant acquisitions has Aurora made recently?

Aurora acquired the remaining equity interest in MedReleaf Australia, strengthening its position in the Australian medical cannabis market.

What certifications do Aurora's production facilities hold?

Aurora's production facilities hold EU-GMP and TGA-GMP certifications, ensuring compliance with rigorous international quality standards.

How does Aurora contribute to the U.S. cannabis market?

Aurora's wholly-owned subsidiary, Australis Capital Inc., actively participates in the U.S. cannabis market.

What international operations does Aurora have?

Aurora has expanded internationally through medical cannabis exporting agreements, with a significant presence in Europe and Australia.

How does Aurora ensure the quality of its products?

Aurora ensures the quality of its products through advanced cultivation techniques and compliance with international standards like EU-GMP and TGA-GMP.

Aurora Cannabis Inc. Common Shares

NYSE:ACB

ACB Rankings

ACB Stock Data

233.50M
54.88M
13.29%
4.8%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Edmonton